THEuse of a radioactive compound as an aid to the diagnosis of an internal cancer would be highly desirable. Previous studies carried out in this laboratory have shown that with certain S35-labeled disulfonamido derivatives of fluorene and biphenyl there is an evident difference in the distribution of these compounds between tumor-bearing and tumor-free animal organisms. The most promising results have been obtained with disodium fluorene-2,7-disulfonate_S3.1 (Argus, 1953) and sulfonated derivative of fluorene-2,7-di(sulfonamido-2-naphthalene)_S35 (Argus and Hewson, 1954Hewson, ) 1955. Both compounds have been tested in tumor-bearing and tumor-free mice and at each time period studied (2, 8 and 32 hours) the ratios of localization in tumor tissue compared to the liver, spleen and also kidneys, blood and muscle were greatly increased.
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On the other hand, an interesting observation has been made with fluorene-2 7-di(sulfonamido-2-naphthalene)_S35 (Argus, Hewson and Ray, 1956 ) and biphenyl-4,4'-di(sulfonamido-benzene_S35-4-sulfonamide) (Argus, Seepe, Gutierrez, Hewson and Ray, 1958) , which have been localized in the liver and spleen of tumor-free mice to a greater extent than in tumor-bearers.
Fluorene-2,7-di(sulfonamido-2-naphthalene)_S35 showed the same behavior in hamsters with and without transplanted sarcoma (Argus, Lemasters, Gutierrez and Ray, 1957) . Furthermore, when the tumors were removed the concentration of radioactivity in the liver and spleen returned to the level found in tumor-free animals. The same perception has been reported for male Wistar rats with Walker carcinosarcoma 256 (Argus, Seepe, Kane and Ray, 1958; Argus, 1961) .
To determine if, in the presence of tumor, the decreased uptake of fluorene-2, 7-di(sulfonamido-2-na,phthalene)_S35 by the liver and spleen is a general stress phenomenon, the distribution of this compound has been examined in rats and mice of both sexes after total whole body irradiation of 150 r (Argus, Kane and Ray, 1960) and after cortisone treatment (Malejka, Argus and Ray, 1961) . The results of these experiments showed that the presence of tumor in animals is responsible for the differential uptake of disulfonamide by the liver and spleen.
In the present study two new substances were prepared and examined in tumor-bearing and tumor-free Wistar rats in an attempt to find a favorable liverspleen or tumor localization. These were fluorene-2,7-di(sulfonamidobenzene-S35-4-sulfonamide), 1, and a compound, the analysis of which corresponds to disodium fluorenone-X-nitroso-2,7-di(sulfonamidobenzene-S35-4-sulfonate) dihydrate, 11. ,///\-HN-02S \/\//\-SO2-NH
Radioactive S-3-1.
The chemical structures of both compounds are closely related to the group of high molecular weight disulfonamides which were reported on previously. Compound I is an analog of a biphenyl derivative which was tested in mice (Argus, Seepe, Gutierrez, Hewson and Ray, 1958) , and compound 11 was obtained from I by reaction with nitrous anhydride, since this method was reported to be satisfactory in the case of carboxy amides extremely resistant to hydrolysis (Hurd and Sowden, 1938 ; Sperber, Papa and Schwenk, 1948) . However, in the described case this resulted, in addition to removal of the amido groups, in a compound the analysis of which corresponds to disodium fluorenone-X-nitroso-2,7-di(sulfonamidobenzene_S35-4-sulfonate) dihydrate, indicating supplementary introduction of a nitroso group and oxidation in the 9 position. While this was a more profound change than we had intended, it-, nevertheless, seemed of interest to compare the behavior of this less usual derivative with those previously studied.
MATERIALS AND METHODS
Fluorene-2)7-disulfonyl chloride-S35.-The procedure described previously (Argus and Hewson, 1954) The sodium salt shaken with Amberlite IR-120 gave the free sulfonic acid derivative as a glass, which decomposed at 2_95'. It was not f-Lirther examined, but was converted iiito the mono-p-toluidine salt, which melted at 235'. This retained one molecule of water.
Analy8is.-Calculated for C32H2,,N C, 47-75 ; H, 3-51 N, 6-96 ; 8, 15-94. Found: C, 47-91 ; H, 3-99 ; N, 7-30; 8, 15-25. Animal experiment8.-A total of '24 male Wistar rats, weanlings, was used; I I were employed for the subcutaneous transplantation of Walker carcinosarcoma 256, now in its 115th generation transplant in this laboratory ; 13 tumor-free rats served as control groups. When the tumors were 10-12 days old, and averaged 12 g. in weight, the radioactive compounds were administered by tail vein injections. Each rat was given 1-2 ml. 0-05 N sodium hydroxide containing 12 mg. fliiorene---),7-di(sulfonamidobenzene-835-4-sulfonamide), 1, or disodium fluorenone-X-nitroso-2, 7-di(sulfonamidobenzene-S35-4-sulfonate) dihydrate, 11, and then placed in an individual metabolism caae and killed 6 hours following administra tioii of the compounds. Concentration and per cent recovery of radioactive material in tissues and excreta of rats were determined by methods previously described (Argus, Kane and Ray, 1960 The distribution in the skin and carcass for both compounds seems to be somewhat related to this phenomenon since considerably more radioactivity is found for II in these tissues. Considering differences in localization of S35-labeled compounds between experimental and control animals, the ratios of concentration of radioactivity in blood cells, blood plasma, liver, spleen and uring of tumor-free Wistar rats to the concentration in the same tissues of tumor-bearers 6 hours following intravenous injection of compounds I and II are presented in Table II . In most cases the ratio I Average value from 5 rats. § Based on null hypothesis for true difference between experimental (tumor-bearing) and control (tumor-free) groups' values. ¶ Average value from 7 rats and 5 rats in the cases of blood cells and plasma.
is close to 1.00, or reveals no significant difference (0.2 < P < 0.3) in compound localization between control and experimental organs. Exceptions are ratios for the liver and spleen of compound I. The liver of control rats took 1.54 times more radioactive substance than liver of experimental animals. The uptake of radioactivity by control spleen is 4-00 times greater than by the experimental organ. Both these values indicate an evident functional change of the liver and spleen caused by the presence of Walker carcinosarcoma 256, and offer, therefore, a possible diagnostic tool. Comparing values (2.52 for the liver and 1.72 for the spleen) which were reported by Argus (1961) for fiuorene-2,7-di(sulfonamido-2-naphthalene)-S35, the uptake of fiuorene-2,7-di(sulfonamidobenzene-S35-4-sulfonamide) by control liver is somewhat less, but the ratio for the spleen is considerably increased. Probability values (_0. 1 and 0.001 < P < 0.01) appear to be signifi-cant. The most striking difference between control and experimental animals is found in the urine after a single injectioii of fluorene-2,7-di(sulfonamidobenzene-S35-4-sulfonamide), 1. The increased excretion of compound to urine by experimental rats is significant (P -0-001), and together with the decreased values of concentration in the liver and spleen of tumor-bearers indicate an affected metabolism of this S35-labeled compound in the presence of tumor.
A more favorable localization in tumor is found using compound 11. This observation is in agreement with previous findings in mice (Argus, 1953; Argus and Hewson, 1954) , that the presen Ice of sulfonic acid groups in the fluorene or its derivative molecule increased the concentration of radioactivity in tumor. The molecular weight of the compound is also to be considered : the sulfonic acid derivative investigated in the present study has the molecular weight falling between the compounds previously tested : fluorene-2,7-disulfonic acid-S35 (Argus, 1953) and sulfonated derivative of fluorene-2,7-di(sulfonamido-2-naphthalene)-S35 (Argus and Hewson, 1954) . The data obtained with disodium fluorenone-X-nitroso-2,7-di(sulfonamidobenzene-S35-4-sulfonate) dihydrate show that for liver, lung, spleen, thymus, leg muscle, stomach and carcass the ratio values are greater than 1-00 (see column 3 in Table 1 ). For organs of a particular importance such as liver and spleen they are 1-50 and 3-37, respectively, thus revealing diagnostic possibilities.
In conclusion, these studies in Wistar rats with Walker carcinosarcoma 256 appear to support previous postulates that compounds with primary sulfonamido groups have a tendency to concentrate in the liver and spleen of tumor-free animals to a greater extent than in tumor-bearers. Secondly, sulfonic acid groups provide a more favorable tumor localization than the sulfonamido groups. The optimal number of sulfonic acid groups, their most effective position and the most satisfactory sized molecule, however, have not yet been established.
SUMMARY
Two new radioactive compounds: fluorene-2,7-di(sulfonamidobenzene-S35-4-sulfonamide), 1, and disodium fluorenone-X-nitroso-2,7-cli(sulfonamidobenzene-S35-4-sulfonate) dihydrate, 11, have been prepared and their tissue distribution following a single intravenous injection to tumor-bearing and tumor-free Wistar rats has been studied. While the distribution of compound I is affected by the presence of tumor, compound 11 shows no evident difference between experimental and control organs. In the tumor-bearing rats this compound has, however, a greater concentration of radioactivity in tumor tissue as compared with liver, leg muscle, carcass, spleen and thymus. Compound I has a tendency to localize in the liver and spleen of control animals to a greater extent than in tumor-bearers. The ratios found for the liver (1-54) and spleen (4-00), together with the considerably increased excretion of this compound in the urine of experimental rats, indicate a possible diagnostic tool.
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